eli lilly clinical trials tirzepatide is one step closer to gaining access to one of the world's largest weight loss markets Lilly's triple agonist delivers up

In addition to doubling its capacity by the end of 2023, LLY expects production of sellable doses in the second half of 2024 with be at least 1.5x the production in the second half of 2023

Obesity is equally defined in older and younger adults using a BMI 30 kg/m 2 , with ethnic specific BMI thresholds [14], although surrogate markers of fat mass and distribution, such as waist circumference (WC) and height-to-weight ratio, may more accurately define body composition in older adults [15]

Healthcare providers and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval

JAD helped with study design

Am J Physiology-Lung Cell Mol Physiol 309:L369L377 de Araujo Junior RF, da Silva Reinaldo MPO, de Castro Brito GA, de Cavalcanti Franca P, de Moura Freire MA, de Medeiros CAX, de Araujo AA (2014) Olmesartan decreased levels of IL-1 and TNF-, down-regulated MMP-2, MMP-9, COX-2, RANK/RANKL and up-regulated SOCs-1 in an intestinal mucositis model